http://www.onclive.com/onclive-tv/dr-janni-on-the-benefits-of-targeted-therapies-for-her2positive-breast-cancer
Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD



Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 
Printer Printing...